A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendoc...
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors
About this item
Full title
Author / Creator
Perez, Kimberly , Kulke, Matthew H , Zheng, Hui , Allen, Jill , Clark, Jeffrey , Enzinger, Andrea C , Enzinger, Peter C , Johnson, Bruce E , McCleary, Nadine J , Parikh, Aparna , Patel, Anuj , Rubinson, Douglas , Yurgelun, Matthew B , Ramsey, Kaitlyn , Johnson, Emma , Graham, Christopher and Chan, Jennifer A
Publisher
US: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
US: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Abstract
Objectives
Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with soma...
Alternative Titles
Full title
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11753395
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11753395
Other Identifiers
ISSN
1083-7159,1549-490X
E-ISSN
1549-490X
DOI
10.1093/oncolo/oyae364
